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a b s t r a c t
Catheter-based renal denervation (RDN) was considered as a promising method for treat-
ment of resistant hypertension and was increasingly being used worldwide. However, there
are equivocal results from only two randomized trials studying the effect of such interven-
tion. Thus, additional data from properly designed long-term comparative trials are needed.
The PRAGUE-15 trial is designed as an open, prospective, randomized multicenter trial
comparing RDN versus intensiﬁed medical treatment in patients with resistant hyperten-
sion. Patients randomized to the medical treatment group will receive spironolactone in the
absence of contraindications. The primary endpoint will be changes in systolic and diastolic
pressure during ambulatory blood pressure monitoring (ABPM) from baseline to 6 months.
Herein, we describe the trial design and methodology. The strengths of the trial include
ABPM (as the objective endpoint), independent outcomes assessment, and therapeutic use
of spironolactone.
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Introduction
Hypertension is highly prevalent and is the most important
risk factor for development of cardiovascular disease and
mortality [1,2]. The risk of development of cardiovascular
disease is linearly related to both systolic and diastolic blood
pressure (BP) [3]. Despite pharmacological advances in the
area, effective control of BP remains poor [4,5]. Several factors
contribute to this problem. Apart from prescription of
inappropriate drugs, inadequate dosing, and non-adherence
to treatment, approximately 10–15% of patients are resistant to
three or more antihypertensive drugs including diuretics [6].
Recently, catheter-based renal denervation (RDN) has been
considered to be a promising method for treatment of patients
with resistant hypertension [7]. However, the rapid adoption of
the procedure worldwide has been based on the outcome of
one small randomized SYMPLICITY HTN-2 trial comparing
RDN with antihypertensive treatment [8]. Nevertheless,
recently published SYMPLICITY HTN-3 trial did not show a
signiﬁcant reduction of systolic blood pressure in patients with
resistant hypertension 6 months after RDN as compared with a
Table 1 – Inclusion and exclusion criteria.
Inclusion criteria
 Resistant hypertension with ofﬁce systolic blood pressure
of >140 mmHg
 Systolic blood pressure of >130 mmHg during 24-h ambulatory
blood pressure monitoring
 Treatment with at least three antihypertensive medications,
including diuretics, at optimal doses
 Age of >18 years
 Signed informed consent
Exclusion criteria
 Any secondary form of hypertension
 Non-compliance with medical treatment
 Presence of any chronic renal disease (serum creatinine
level of >200 mmol/l)
 Pregnancy
 History of myocardial infarction or stroke in the previous 6
months
 Presence of severe valvular stenotic disease
 Anatomical abnormality or a variant structure of either renal
artery, including aneurysm, stenosis, a reference diameter
of <4 mm, and a length of <20 mm
 An increased bleeding risk (thrombocytopenia of <50,000
platelets/ml of blood and an INR of >1.5)
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long-term comparative trials can help to establish the role of
RDN in comparison to that of optimal drug treatment [6,10]. In
the latter context, spironolactone has recently been shown to
effectively lower BP in patients with resistant hypertension
[11].
Therefore, we designed a multicenter randomized trial
comparing the effect of catheter-based RDN versus intensiﬁed
antihypertensive treatment (including use of antagonists of
mineralocorticoid receptors) in patients with conﬁrmed
resistant hypertension.
PRAGUE-15 study design
The PRAGUE-15 study was designed as an academic, investi-
gator-initiated, open, prospective, multicenter randomized
trial (clinicaltrial.gov identiﬁer: NCT 01560312). Patients with
resistant hypertension were randomized (in a 1:1 ratio) to
either catheter-based RDN plus optimal antihypertensive
treatment (unchanged after randomization and without
treatment with spironolactone) or optimal antihypertensive
treatment (including spironolactone in all patients if not
contraindicated after randomization). Three centers in the
Czech Republic anticipated to enroll 120 patients. The study
has been approved by a multicenter ethics committee and by
all three local institutional ethics committees.
The inclusion and exclusion criteria are shown in Table 1.
During screening, resistant hypertension had to be conﬁrmed
both by ofﬁce BP measurement and 24-h ABPM. All patients
were examined in a hypertension center to exclude most
common forms of secondary hypertension (e.g., primary
aldosteronism, pheochromocytoma, Cushing's syndrome,
renal parenchymal disease, renovascular hypertension,
drug-induced hypertension, and other conditions). Primary
aldosteronism was diagnosed on the basis of an elevated
serum aldosterone:renin ratio and failure to suppress aldoste-
rone secretion after saline infusion, in line with acceptedguidelines for diagnosis and treatment of primary aldosteron-
ism [12]. For patients previously treated with spironolactone,
randomization was performed 3–4 weeks after spironolactone
withdrawal if all other criteria are met. Patients with known
clear contraindications to spironolactone treatment during
the screening period did not enter the study. Adherence to
treatment was tested in all patients by unannounced
quantitative measurements of plasma drug levels during the
screening period before the randomization. Absence of at least
one prescribed antihypertensive agent indicated that a patient
was non-compliant, and that patient was then excluded from
the study. Sampling was conducted at least 3 h after planned
drug intake, during the expected half-life of the drug [13].
Liquid chromatography–dual mass spectrometry (LC/MS/MS)
[14] was performed using a 3200 Q-trap triple quadrupole/
linear ion trap mass spectrometer ﬁtted with a TurboIonSpray
source (MDS Sciex, Ontario, Canada). A rapid and sensitive LC/
MS/MS method for simultaneous determination of doxazosine
and verapamil in human serum has been developed in our
toxicology laboratory [15]. Renal anatomy was evaluated
during screening using CT or MR angiography.
The differences in systolic and diastolic BP recorded by 24-h
ABPM between baseline and 6 months post-randomization is
the primary endpoint of the study. Secondary endpoints
include differences in systolic and diastolic BP recoded by
ABPM and in the ofﬁce between baseline and 1 year, 2 years,
and 3 years post-randomization, as well as changes in
standard clinical and laboratory parameters including renal
function and post-denervation renal anatomy analyzed using
CT or MR angiography 1 year after trial commencement.
Another secondary endpoint is the effect of RDN on the
medically treated group and the effect of spironolactone in the
RDN group 1 year after randomization of patients exhibiting
poor BP control.
Renal denervation procedures were performed using the
Symplicity Renal Denervation System (Medtronic Inc., Moun-
tain View, CA). Treatment involved at least four applications of
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Each treatment was delivered in a helical fashion within the
artery via rotation of the catheter, and the pullback between
ablations was approximately 5 mm.
After randomization, patients selected for RDN are main-
taining on baseline medical therapy for 1 year. Patients
selected for intensiﬁed medical treatment receive baseline
medical therapy and spironolactone (25 mg daily) if no
contraindication is evident. One year after randomization,
patients in the medical treatment group may elect to undergo
the RDN procedure after consultation with physicians and
formation of informed preferences based on BP level. Similar-
ly, spironolactone treatment may be commenced after 1 year
in the RDN group if BP does not attain target levels. The precise
design of the study is shown in Fig. 1. Changes in baseline
pharmacological therapy were allowed only for important
clinical reasons.
For power calculation of the ﬁnal sample size of the
study, the treatment response in each group was deﬁned asFig. 1 – Design of the Pa >5-mmHg decrease in the systolic and diastolic BP during
24-h ABPM between baseline and 6 months post-randomi-
zation (both BP compounds must be decreased to assign
responders). We assumed 60% responders in the RDN group
and 30% responders in the group with intensiﬁed medical
treatment based on existing data [11,16,17]. A total of 112
patients (56 patients in each group) were thus needed to
attain 90% power to demonstrate differences between
groups at a two-sided alpha level of 0.05. If anticipated
that approximately 5% of patients will prematurely with-
draw from the study or become lost to follow-up, a total of
120 patients were needed to be randomized.
Nevertheless, the study was prematurely terminated on
February 10, 2014. After the announcement that SYMPLICITY
HTN-3 failed to meet its primary efﬁcacy endpoint, we ﬁrstly
suspended the study on January 10, 2014 and we subsequently
performed the analysis of actual data of 106 enrolled patients.
Based on the results of this analysis, we decided deﬁnitely to
terminate the study.RAGUE-15 study.
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The study was developed to assess the utility of catheter-
based RDN in a setting of ‘‘truly’’ resistant hypertension when
intensiﬁed combination antihypertensive therapy is used.
Several differences are evident between the methodology of
the present trial and those of previous trials that studied the
utility of RDN in treatment of resistant hypertension [8,18–20].
First, 24-h ABPM data were required for diagnosis of resistant
hypertension and for evaluation of the primary endpoint. To
date, information on lowering BP after performance of the RDN
procedure in published trials have been mainly based on ofﬁce
BP measurements. However, available data from the ABPM
show remarkably lower effect on BP reduction [16,21,22].
Further, ABPM is, in general, a more sensitive predictor of the
risk of adverse clinical cardiovascular outcomes than is ofﬁce BP
[6]. SYMPLICITY HTN-3 trial assessed the comparison of mean
systolic 24-h ABPM change from baseline to 6 months in RDN
and control arm as powered secondary effectiveness endpoint
[9]. In our study, the primary endpoint is the differences in both
systolic and diastolic BP recorded by 24-h ABPM between
baseline and 6 months post-randomization.
Second, evaluation of adherence to treatment is an
important feature of our study. Plasma drug levels were
measured. This was not performed in any prior study
evaluating the effect of RDN on resistant hypertension.
Changes in treatment compliance before and after RDN may
have a considerable effect on BP.
Third, it has recently been shown that spironolactone
safely and effectively reduces BP in truly resistant hyperten-
sive patients [11,17]. The drug is now often prescribed by
specialists when the target BP cannot be achieved using
combinations of three or four antihypertensive drugs. There-
fore, we decided to add spironolactone as a baseline
antihypertensive treatment for patients randomized to the
medical treatment group. Further, the effect of spironolactone
in those who do not respond to RDN was evaluated 1 year after
randomization as will the effect of RDN on those receiving
drugs including spironolactone.
A limitation of the study was that the power calculation
was based on limited data regarding changes in 24-h ABMP
[11,16,17]. Furthermore, the calculation of the efﬁcacy of the
primary endpoint was based on BP changes in individuals in
contrast with the average BP changes used in power calcula-
tion in the SYMPLICITY HTN-3 trial [23]. We are also deﬁning a
treatment response as a decrease in both systolic and diastolic
BP because cardiovascular events are linearly related to both
systolic and diastolic BP [3,24]. Even though the study was
prematurely terminated, the number of enrolled patients
almost reached the planned study size and is thus the second-
third largest randomized study on renal denervation - the
patients number is (just by chance) exactly the same as in
SYMPLICITY HTN-2 trial.
Conﬂict of interest
All authors declare that they have no conﬂict of interest to
disclose.Funding
PRAGUE-15 study was partially supported by the PRVOUK P35
Research Program of the Charles University.
Ethical statement
Hereby we state, that the research was done according to
ethical standards.
Informed consent
Hereby we state that patients enrolled to the study agreed to
participate in the research and signed the informed consent
allowed by ethical committees.
r e f e r e n c e s
[1] P.M. Kearney, M. Whelton, K. Reynolds, et al., Global burden
of hypertension: analysis of worldwide data, Lancet 365
(9455) (2005) 217–223.
[2] C.M. Lawes, S. Vander Hoorn, A. Rodgers, Global burden of
blood-pressure-related disease, Lancet 371 (9623) (2001)
1513–1518, 2008.
[3] S. Lewington, R. Clarke, N. Qizilbash, et al., Age-speciﬁc
relevance of usual blood pressure to vascular mortality: a
meta-analysis of individual data for one million adults in
61 prospective studies, Lancet 360 (9349) (2002)
1903–1913.
[4] D.M. Lloyd-Jones, J.C. Evans, D. Levy, Hypertension in adults
across the age spectrum: current outcomes and control in
the community, Journal of the American Medical
Association 294 (4) (2005) 466–472.
[5] D.A. Calhoun, D. Jones, S. Textor, et al., Resistant
hypertension: diagnosis, evaluation, and treatment: a
scientiﬁc statement from the American Heart Association
Professional Education Committee of the Council for High
Blood Pressure Research, Circulation 117 (25) (2008) e510–e526.
[6] G. Mancia, R. Fagard, K. Nirkiewicz, et al., 2013 ESH/ESC
Guidelines for the management of arterial hypertension:
The Task Force for the management of arterial
hypertension of the European Society of Hypertension (ESH)
and of the European Society of Cardiology (ESC), European
Heart Journal 34 (28) (2013) 2159–2219.
[7] Y. Huan, D.L. Cohen, Renal denervation: a potential new
treatment for severe hypertension, Clinical Cardiology 36
(1) (2013) 10–14.
[8] M.D. Esler, H. Krum, P.A. Sobotka, et al., Renal sympathetic
denervation in patients with treatment-resistant
hypertension (the Symplicity HTN-2 Trial): a randomised
controlled trial, Lancet 376 (9756) (2010) 1903–1909.
[9] D.L. Bhatt, D.E. Kandzari, W.W. O'Neill, et al., A controlled
trial of renal denervation for resistant hypertension, New
England Journal of Medicine 370 (15) (2014) 1393–1401.
[10] P. Widimsky, J. Filipovsky, J. Widimsky Jr., et al., Expert
consensus statement of the Czech Society of Cardiology
and the Czech Society of Hypertension on catheter-based
sympathetic renal denervation procedures (RDN) in the
Czech Republic, Cor et Vasa 54 (2012) e108–e112.
[11] J. Vaclavik, R. Sedlak, M. Plachy, et al., Addition of
spironolactone in patients with resistant arterial
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 2 3 5 – e 2 3 9 e239hypertension (ASPIRANT): a randomized, double-blind,
placebo-controlled trial, Hypertension 57 (6) (2011) 1069–1075.
[12] J.W. Funder, R.M. Carrey, C. Fardella, et al., Case detection,
diagnosis, and treatment of patients with primary
aldosteronism: an endocrine society clinical practice
guideline, Journal of Clinical Endocrinology and Metabolism
93 (9) (2008) 3266–3281.
[13] B. Strauch, O. Petrak, T. Zelinka, et al., Precise assessment of
noncompliance with the antihypertensive therapy in patients
with resistant hypertension using toxicological serum
analysis, Journal of Hypertension 31 (12) (2013) 2455–2461.
[14] O. Gonzalez, R.M. Alonso, N. Ferreirós, et al., LC–MS/MS
method for the determination of several drugs used in
combined cardiovascular therapy in human plasma,
Journal of Chromatography B-Analytical Technologies in
the Biomedical and Life Sciences 878 (28) (2010) 2685–2692.
[15] L. Chytil, B. Strauch, J. Cvacka, et al., Determination of
doxazosin and verapamil in human serum by fast LC–MS/
MS: application to document non-compliance of patients,
Journal of Chromatography B-Analytical Technologies in
the Biomedical and Life Sciences 878 (30) (2010) 3167–3173.
[16] F. Mahfoud, C. Ukena, R.E. Schmieder, et al., Ambulatory
blood pressure changes after renal sympathetic
denervation in patients with resistant hypertension,
Circulation 128 (2) (2013) 132–140.
[17] F. de Souza, E. Muxfeldt, R. Fiszman, et al., Efﬁcacy of
spironolactone therapy in patients with true resistant
hypertension, Hypertension 55 (1) (2010) 147–152.[18] S.G. Worthley, C.P. Tsiouﬁs, M.I. Worthley, et al., Safety
and efﬁcacy of a multi-electrode renal sympathetic
denervation system in resistant hypertension: the
EnligHTN I trial, European Heart Journal 34 (28) (2013)
2132–2140.
[19] Symplicity HTN-1 Investigators, Catheter-based renal
sympathetic denervation for resistant hypertension:
durability of blood pressure reduction out to 24 months,
Hypertension 57 (5) (2011) 911–917.
[20] P. Widimsky, P. Osmancik, J. Widimsky Jr., et al., Renal
denervation: the hope for patients with refractory
hypertension? Cor et Vasa 53 (2011) 517–521.
[21] G. Grassi, R. Facchetti, G. Seravalle, et al., Home and
ambulatory blood pressure in resistant hypertension,
EuroIntervention 9 (Suppl. R) (2013) R35–R41.
[22] A. Persu, M. Azizi, M. Burnier, et al., Residual effect of renal
denervation in patients with truly resistant hypertension,
Hypertension 62 (3) (2013) 450–452.
[23] D.E. Kandzari, D.L. Bhatt, P.A. Sobotka, et al., Catheter-
based renal denervation for resistant hypertension:
rationale and design of the SYMPLICITY HTN-3 Trial,
Clinical Cardiology 35 (9) (2012) 528–535.
[24] R. Sega, R. Facchetti, M. Bombelli, et al., Prognostic value of
ambulatory and home blood pressures compared with
ofﬁce blood pressure in the general population: follow-up
results from the Pressioni Arteriose Monitorate e Loro
Associazioni (PAMELA) study, Circulation 111 (14) (2005)
1777–1783.
